PEAK6’s Ocular Therapeutix OCUL Stock Holding History

PEAK6’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$262K	Hold	26,656	–	–	﹤0.01%	2198
2026 Q1	$226K	Buy	+26,656	New	+$254K	﹤0.01%	2239

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PEAK6's OCUL Position: Q2 2026 in Review

PEAK6 held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 26,656 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #2198.

PEAK6 first reported a position in OCUL in Q1 2026 and has held it in 2 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

PEAK6 held 26,656 shares of Ocular Therapeutix worth $262K as of Q2 2026.
PEAK6 left its Ocular Therapeutix share count unchanged in Q2 2026.
Ocular Therapeutix made up ﹤0.01% of PEAK6's portfolio in Q2 2026, its #2198 holding.
PEAK6 first reported a position in Ocular Therapeutix in Q1 2026 and has held it in 2 quarters since.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on PEAK6's 13F filing for Q2 2026, filed 13 Aug 2026.